SkinBit has raised $6.0M in pre-seed funding, a notable early bet on a company aiming to overhaul how skin cancer is caught. The round’s backers weren’t disclosed, but the capital gives the startup runway to push its detection technology forward.
The company’s pitch is straightforward: skin cancer detection is ripe for a rethink, and SkinBit is building tools to make it faster and more precise. At a pre-seed stage, this size of check signals serious conviction-though without named investors, the market will be watching for who’s behind it and what SkinBit delivers next.
